Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Europe AG”

3 pharma patents match "Alnylam Europe AG" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 3
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 3 pharmaceutical patents matching "Alnylam Europe AG" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

3 results for “Alnylam Europe AG” · 30,257 patents in full index Clear search

  1. US 7473525

    Compositions and methods for inhibiting expression of anti-apoptotic genes

    Alnylam Europe AG · Granted Jan 6, 2009 · Expires Jan 1, 2029

    granted

  2. US 7348314

    Compositions and methods for inhibiting viral replication

    Alnylam Europe AG · Granted Mar 25, 2008 · Expires Mar 20, 2028

    granted

  3. US 7196184

    Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene

    Alnylam Europe AG · Granted Mar 27, 2007 · Expires Mar 22, 2027

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.